These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 33401109)

  • 1. CT-based whole-body tumor volumetry versus RECIST 1.1: Feasibility and implications for inter-reader variability.
    Zimmermann M; Kuhl CK; Engelke H; Bettermann G; Keil S
    Eur J Radiol; 2021 Feb; 135():109514. PubMed ID: 33401109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Volumetric measurements of target lesions: does it improve inter-reader variability for oncological response assessment according to RECIST 1.1 guidelines compared to standard unidimensional measurements?
    Zimmermann M; Kuhl C; Engelke H; Bettermann G; Keil S
    Pol J Radiol; 2021; 86():e594-e600. PubMed ID: 34876940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intra- and inter-reader agreement of iRECIST and RECIST 1.1 criteria for the assessment of tumor response in patients receiving checkpoint inhibitor immunotherapy for lung cancer.
    Huicochea Castellanos S; Pagano A; Plodkowski AJ; Girshman J; Hellmann MD; Rizvi H; Flynn J; Zheng J; Capanu M; Halpenny DF; Ginsberg MS
    Lung Cancer; 2021 Nov; 161():60-67. PubMed ID: 34536733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Target lesion selection: an important factor causing variability of response classification in the Response Evaluation Criteria for Solid Tumors 1.1.
    Keil S; Barabasch A; Dirrichs T; Bruners P; Hansen NL; Bieling HB; Brümmendorf TH; Kuhl CK
    Invest Radiol; 2014 Aug; 49(8):509-17. PubMed ID: 24651664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Volume-based response evaluation with consensual lesion selection: a pilot study by using cloud solutions and comparison to RECIST 1.1.
    Oubel E; Bonnard E; Sueoka-Aragane N; Kobayashi N; Charbonnier C; Yamamichi J; Mizobe H; Kimura S
    Acad Radiol; 2015 Feb; 22(2):217-25. PubMed ID: 25488429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Volumetry: an alternative to assess therapy response for malignant pleural mesothelioma?
    Frauenfelder T; Tutic M; Weder W; Götti RP; Stahel RA; Seifert B; Opitz I
    Eur Respir J; 2011 Jul; 38(1):162-8. PubMed ID: 21273389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Volumetric Versus Unidimensional Measures of Metastatic Colorectal Cancer in Assessing Disease Response.
    Lubner MG; Stabo N; Lubner SJ; Del Rio AM; Song C; Pickhardt PJ
    Clin Colorectal Cancer; 2017 Dec; 16(4):324-333.e1. PubMed ID: 28433601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validity of RECIST Version 1.1 for Response Assessment in Metastatic Cancer: A Prospective, Multireader Study.
    Kuhl CK; Alparslan Y; Schmoee J; Sequeira B; Keulers A; Brümmendorf TH; Keil S
    Radiology; 2019 Feb; 290(2):349-356. PubMed ID: 30398433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soft Tissue Sarcoma Response to Two Cycles of Neoadjuvant Chemotherapy: A Multireader Analysis of MRI Findings and Agreement with RECIST Criteria and Change in SUVmax.
    Favinger JL; Hippe DS; Davidson DJ; Elojeimy S; Roth ES; Lindberg AW; Ha AS
    Acad Radiol; 2018 Apr; 25(4):470-475. PubMed ID: 29273189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response.
    Erasmus JJ; Gladish GW; Broemeling L; Sabloff BS; Truong MT; Herbst RS; Munden RF
    J Clin Oncol; 2003 Jul; 21(13):2574-82. PubMed ID: 12829678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lung, liver and lymph node metastases in follow-up MSCT: comprehensive volumetric assessment of lesion size changes.
    Wulff AM; Bolte H; Fischer S; Freitag-Wolf S; Soza G; Tietjen C; Biederer J; Heller M; Fabel M
    Rofo; 2012 Sep; 184(9):820-8. PubMed ID: 22872601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interobserver and intraobserver variability in the response evaluation of cancer therapy according to RECIST and WHO-criteria.
    Suzuki C; Torkzad MR; Jacobsson H; Aström G; Sundin A; Hatschek T; Fujii H; Blomqvist L
    Acta Oncol; 2010 May; 49(4):509-14. PubMed ID: 20397778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Observer variability in a phase II trial - assessing consistency in RECIST application.
    Skougaard K; McCullagh MJ; Nielsen D; Hendel HW; Jensen BV; Johannesen HH
    Acta Oncol; 2012 Jul; 51(6):774-80. PubMed ID: 22432439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the agreement between tumour volumetry and the estimated volumes of tumour lesions using an algorithm.
    Laubender RP; Lynghjem J; D'Anastasi M; Heinemann V; Modest DP; Mansmann UR; Sartorius U; Schlichting M; Graser A
    Eur Radiol; 2014 Jul; 24(7):1521-8. PubMed ID: 24816938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Volumetric response classification in metastatic solid tumors on MSCT: initial results in a whole-body setting.
    Wulff AM; Fabel M; Freitag-Wolf S; Tepper M; Knabe HM; Schäfer JP; Jansen O; Bolte H
    Eur J Radiol; 2013 Oct; 82(10):e567-73. PubMed ID: 23827800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prediction of pouch of Douglas obliteration using offline analysis of the transvaginal ultrasound 'sliding sign' technique: inter- and intra-observer reproducibility.
    Reid S; Lu C; Casikar I; Mein B; Magotti R; Ludlow J; Benzie R; Condous G
    Hum Reprod; 2013 May; 28(5):1237-46. PubMed ID: 23482338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Towards volumetric thresholds in RECIST 1.1: Therapeutic response assessment in hepatic metastases.
    Winter KS; Hofmann FO; Thierfelder KM; Holch JW; Hesse N; Baumann AB; Modest DP; Stintzing S; Heinemann V; Ricke J; Sommer WH; D'Anastasi M
    Eur Radiol; 2018 Nov; 28(11):4839-4848. PubMed ID: 29736851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intra- and inter-observer variability in measurement of target lesions: implication on response evaluation according to RECIST 1.1.
    Muenzel D; Engels HP; Bruegel M; Kehl V; Rummeny EJ; Metz S
    Radiol Oncol; 2012 Mar; 46(1):8-18. PubMed ID: 22933974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the capability and reproducibility of RECIST 1.1. measurements by technologists in breast cancer follow-up: a pilot study.
    Gouel P; Callonnec F; Levêque É; Valet C; Blôt A; Cuvelier C; Saï S; Saunier L; Pepin LF; Hapdey S; Libraire J; Vera P; Viard B
    Sci Rep; 2023 Jun; 13(1):9148. PubMed ID: 37277412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discrepancies of assessments in a RECIST 1.1 phase II clinical trial - association between adjudication rate and variability in images and tumors selection.
    Beaumont H; Evans TL; Klifa C; Guermazi A; Hong SR; Chadjaa M; Monostori Z
    Cancer Imaging; 2018 Dec; 18(1):50. PubMed ID: 30537991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.